Introduction {#S1}
============

Azole resistance (Azole-R) in *Aspergillus fumigatus* is an increasing problem and complicates patient management ([@B31]). Azole-R *A. fumigatus* in patients with cystic fibrosis (CF) has been reported in several studies ([@B34]; [@B9]; [@B33]; [@B8]; [@B18]; [@B49]; [@B41]; [@B1]; [@B21]; [@B23]; [@B45]; [@B16]; [@B30]; [Table 1](#T1){ref-type="table"}). Danish CF patients are followed up monthly at the two specialized CF clinics at Copenhagen University Hospital, Rigshospitalet (RH) and at Aarhus University Hospital (AUH). From the majority of these patients, airway samples are obtained monthly. We have previously studied azole-R *A. fumigatus* in the Copenhagen CF cohort ([@B34], [@B35]). The first study included isolates from Jan to March (Q1) 2007 ([@B35]) and the second study isolates from July to Dec (Q3-4) of 2007 and of 2009 ([@B34]). These studies documented an overall azole-non-susceptibility rate of 1.6 and of 4.5%, respectively. A lower but increasing rate from 1.8 to 3.8% of azole-R *A. fumigatus* among clinical samples (from CF as well as non-CF patients in Denmark) was found in a subsequent reference laboratory-based study, from the years 2010 to 2014 ([@B29]). But the epidemiology of azole-R *A. fumigatus* including that specifically associated with environmental origin has not been systematically studied over a longer time in our country. Due to the increasing international and political concern related to the link between environmental azole fungicide use and azole resistance in *A. fumigatus*, we systematically investigated the azole resistance rate in the Danish CF population in 2018 and compared it to our previous data ([@B34]).

###### 

Review of published studies on azole resistance in patients with cystic fibrosis.

  Study and year of publication   Country          Azole resistance rate at patient level                No. CF patients with *A. fumigatus*   No. *A. fumigatus* isolates in CF patients   Reported number of CF patients with *A. fumigatus* harboring a mutation of environmental origin           Reported number of CF patients with *A. fumigatus* harboring a mutation of non-environmental origin
  ------------------------------- ---------------- ----------------------------------------------------- ------------------------------------- -------------------------------------------- --------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------
  [@B2]                           Portugal         0%\*                                                  11                                    159                                          None                                                                                                      None
  [@B34]                          Denmark          4.5%                                                  133                                   413                                          2/133 (1.5%) with TR~34~/L98H                                                                             4/133 (3%) one M220K, one Y4131C, one M220I and one non-*CYP51A* mutation
  [@B9]                           France           4.6%                                                  131                                   285                                          2/131 (1.5%) with TR~34~/L98H                                                                             4/131 (3.1%) one G54E, one M220I, one M220R and one non-*CYP51A* mutation
  [@B33]                          France           8%                                                    50                                    85                                           3/50 (6%) with TR~34~/L98H                                                                                2/50 (4%) one M220T and one with TR~34~/L98H, G54R and M220T
  [@B8]                           Germany          5.5%\*\*                                              na for cystic fibrosis                163                                          Three isolates with TR~34~/L98H\*\*\*                                                                     One isolate with M220I, one isolate withF219C and four isolates with non-*CYP51A* mutations were also detected\*\*\*
  [@B18]                          Germany          3.4%                                                  119                                   526                                          3/119 (2.5%). Three patients with TR~34~/L98H of which one with both TR~34~/L98H and TR~46~/Y121F/T289A   1/119 (8.4%) with M220L
  [@B19]                          Poland           0%                                                    na for *A. fumigatus*                 67                                           None                                                                                                      None
  [@B49]                          United States    7%\*\*                                                28                                    30                                           na                                                                                                        na
  [@B41]                          Italy            0% and 8.2% at the two centers                        220                                   423                                          7/220 (3.2%) with TR~34~/L98H                                                                             1/220 (0.5%) with F219I
  [@B1]                           United Kingdom   13.3% overall and 16.2% in CF patients specifically   74                                    N/A for CF patients                          5/74 (6.8%) with TR~34~/L98H                                                                              None
  [@B23]                          Turkey           16.7%                                                 6                                     31                                           None                                                                                                      1/6 (16.7%) non-*CYP51A* mutation
  [@B21]                          France           15.2%                                                 33                                    42                                           1/33 (3%) with TR~34~/L98H                                                                                4/33 (12.1%) one M220K, one G54R and two non-*CYP51A* mutations
  [@B45]                          Germany          5.3%                                                  961                                   2888                                         89 isolates TR~34~/L98H and one isolate with TR~46~/Y121F/T289A\*\*\*                                     Seven G54E, one G54R, one F219S and two non-*CYP51A* mutations\*\*\*
  [@B16]                          Netherlands      7.1%\*\*\*\*                                          558                                   2652                                         5.2% with TR~34~/L98H and 1.4% with TR~46~/T289A/Y121F\*\*\*\*                                            0.2% with M220 and 0.2% with G54W\*\*\*\*
  [@B30]                          France           6.8%                                                  88                                    126                                          4/88 (4.5%). Two with TR~34~/L98H, one with TR~34~/L98H/S297T/F495I and one with TR~46~/Y121F/T289A       2/88 (2.3%) one F46Y/M172V/N248T/D255E/E427K and one non-*CYP51A* mutation

CF: Cystic fibrosis. A. fumigatus: Aspergillus fumigatus na: Not available. \*One patient had one isolate with MIC outside of the epidemiological cut-off of 0.25 μg/mL for posaconazole. \*\*Azole resistance at isolate level in CF patients. \*\*\*The number of mutations per patient was not reported. \*\*\*\*Mean per year.

CF is the most common autosomal recessive disease in Caucasians ([@B17]). Mutations in the CFTR (cystic fibrosis transmembrane regulator gene) affects the chloride transportation causing dysregulated fluid transport in the epithelial cells of multiple organs ([@B17]). Clinically, CF disease is dominated by infectious pulmonary complications ([@B17]). The respiratory tract is often colonized with molds especially *A. fumigatus*, which is found in 16 to 56.7% of airway samples ([@B40]). *Aspergillus* may cause a diversity of manifestations ranging from asymptomatic colonization to serological sensitization, allergic bronchopulmonary aspergillosis (ABPA), *Aspergillus* bronchitis, and aspergilloma in CF patients ([@B17]). The most common is ABPA ([@B40]), which occurs in approximately 10% of CF patients ([@B10]; [@B12]) and is the cause of hypersensitivity response to *Aspergillus* antigens ([@B53]). Azoles are the cornerstone in the management of CF patients with *Aspergillus* disease requiring antifungal therapy. Itraconazole is the first choice as an antifungal drug in the treatment of ABPA to reduce the burden of *A. fumigatus* and minimize use of corticosteroids ([@B38]). Posaconazole is used as salvage therapy in ABPA or bronchitis ([@B46]; [@B39]), whereas voriconazole or isavuconazole are first-line agents ([@B32]; [@B38]) in the rare event of invasive aspergillosis ([@B10]; [@B46]; [@B25]).

Azoles target and inhibit the lanosterol 14-α-demethylase enzyme (Cyp51A) encoded by the *cyp51A* gene and thereby inhibit the ergosterol synthesis ([@B48]). Patients with recurrent or long-term need for azole therapy are at risk for azole-R *Aspergillus* due to selection of resistance during exposure to medical azoles ([@B25]). Azole-R in *A. fumigatus* also occurs in patients with no prior azole therapy, caused by the inhalation of resistant mutant spores from the environment presumably selected due to azole fungicide use for plant and material protection ([@B7]; [@B24]). Well-known mechanisms behind azole resistance are target gene mutations in *cyp51A*. Two common resistance mechanisms, TR~34~/L98H and TR~46~/Y121F/T289A, are considered to be of environmental origin ([@B48]). These "environmental" mechanisms have previously been found in the Danish environment ([@B36]; [@B42]) and in clinical samples ([@B34]; [@B7]). Furthermore, target gene upregulation, efflux, and HapE ([@B11]) and Hmg1 ([@B44]) alterations have been documented as underlying mechanisms of azole resistance in selected isolates.

In this study, we investigated the azole-R rate in a 10-y perspective and dissected underlying molecular resistance mechanisms and genotypes in *Aspergillus* in CF patients followed up at the two Danish CF centers that serve the entire country.

Materials and Methods {#S2}
=====================

The two CF centers RH and AUH follow all the Danish CF patients. A total of 522 (320 and 202 adult and children) with CF were followed up at RH and AUH, respectively, in 2018. All positive cultures with mold from airway samples from the Danish CF population were included during a 6-month (Jan--June 2018) and a 9-month (Jan--Sept 2018) period, respectively, from AUH and RH. Primary culture was performed using Sabouraud glucose agar \[SSI Diagnostika, Hillerød, Denmark (RH) and bioMérieux, Marcy l'Etoile, France (AUH), respectively\]. Agar plates were incubated at 35--37°C and examined for 5 days (RH) and 2 days (AUH). Exclusion criteria were identical to our previous study ([@B34]). In detail, repeat isolates from the same patient were excluded when found ≤30 days apart and confirmed as same species and with same susceptibility classification.

Identification was done to the *Aspergillus* species complex level using classical techniques, including thermo-tolerance test for *A. fumigatus* specifically, followed up by MALDI-TOF applying the Mass Spectrometry Identification database ([@B37]; [@B28]) and β-tubulin sequencing ([@B20]) when necessary.

The EUCAST E.Def 10.1 method ([@B6]) was used for azole-R screening for *A. fumigatus*, and EUCAST E.Def 9.3.1 susceptibility testing ([@B5]) was performed for amphotericin B for the majority of the isolates and for itraconazole, posaconazole, and voriconazole for screening-positive *A. fumigatus* isolates and *Aspergillus* species other than *A. fumigatus*. Isolates with azole MIC(s) above the ECOFF(s) underwent *cyp51A* sequencing as previously described ([@B34]). EUCAST clinical breakpoints v 9.0 were adopted for susceptibility classification into susceptible, non-susceptible (intermediate and resistant), and azole-R ([@B3]). For species and agents without breakpoints, EUCAST ECOFFs were adopted and non-wildtype isolates were regarded resistant. Sequential isolates from all patients harboring resistant *A. fumigatus* underwent STRA*f* genotyping ([@B15]).

Results were compared to our previous Danish studies on azole-R in CF patients followed up at RH allowing a 10-year perspective ([@B34]). Comparison of groups was performed with a contingency chi-square test using GraphPad Prism version 8.0.2.

(Preliminary results from RH have been presented at the European Congress on Clinical Microbiology and Infectious Diseases in 2019).

Results {#S3}
=======

In total, 340 unique mold isolates from 159 CF patients were obtained, of which 240 isolates were derived from 110 CF patients at RH (2.2 isolates per patient) and 100 isolates from 49 CF patients at AUH (2.0 isolates per patient). The median age was 30 years (6--68 years) at RH and 22 years (6--50 years) at AUH among patients with a mold isolate.

Overall, *A. fumigatus* was the most frequently isolated species (266/340 isolates, 78.2%), detected in 137/159 (86.2%) of the CF patients followed up by *A. terreus* species complex (26/340 isolates, 7.6%) in 10/159 patients (6.3%) and *A. niger* complex isolates (13/340 isolates, 3.8%) in 13/159 (8.2%) patients ([Figure 1](#F1){ref-type="fig"}).

![Species distribution at the cystic fibrosis population gathered and at the two centers separately. S, I, and R indicate the susceptibility for azoles. S: susceptible, I: intermediate, and R: resistant. Aarhus (AUH): Other molds: *Scedosporium* spp. (*n* = 8), *Exophiala* spp. (*n* = 2), *Penicillium* spp. (*n* = 1). Rigshospitalet (RH): Other *Aspergillus*: *Aspergillus nidulans* (*n* = 2) and *Aspergillus sydowii* (*n* = 1), *Mucorales: Rhiomucor pusillus* (*n* = 1) *and Zygomycetes* spp. (*n* = 1). Other molds: *Scedosporium* spp. (*n* = 3), and *Rasamsonia* spp. (*n* = 1).](fmicb-11-01850-g001){#F1}

Azole non-susceptible *A. fumigatus* was found in 12/137 (8.8%) and Azole-R *A. fumigatus* in 10/137 (7.3%) of all CF patients ([Table 2](#T2){ref-type="table"}). Eight patients harbored *A. fumigatus* with Cyp51A alterations, including one patient (RH-5) with two isolates with different Cyp51A alterations. Overall, Cyp51A alterations were thus found in 81.8% (9/11) azole-R *A. fumigatus* of which 45.5% (5/11) were of environmental origin ([Table 2](#T2){ref-type="table"}). Three *A. fumigatus* isolates were categorized as intermediate to one or several azoles, none of which harbored *cyp51A* mutations.

###### 

Cyp51A profile for 18 *Aspergillus fumigatus* and *Aspergillus terreus* isolates with decreased susceptibility from 15 CF patients at the two referral centers in Denmark.

  Species/patient ID^a^   Susceptibility classification^b^   Cyp51A profile
  ----------------------- ---------------------------------- -------------------------
  ***A. fumigatus***                                         
  AUH-1                   Intermediate                       Wildtype
  AUH-2                   Resistant                          TR~34~/L98H
  RH-1                    Intermediate                       Wildtype
  RH-2                    Intermediate                       Wildtype
                          Resistant                          Wildtype
  RH-3                    Resistant                          Wildtype
  RH-4                    Resistant                          TR~34~/L98H/S297T/F495I
  RH-5                    Resistant                          TR~34~^3^/L98H
                          Resistant                          TR~34~/L98H
  RH-6                    Resistant                          TR~34~/L98H
  RH-7                    Resistant                          TR~34~/L98H
  RH-8                    Resistant                          M220R
  RH-9                    Resistant                          M220K
  RH-10                   Resistant                          M220K
  ***A. terreus***                                           
  AUH-3                   Resistant                          
  RH-11                   Resistant                          M217I
                          Intermediate                       Y491H
  RH-12                   Resistant                          G51A

a

AUH, Aarhus University Hospital, RH, Rigshospitalet.

b

According to EUCAST clinical breakpoints for antifungals v 9.0, for A. fumigatus an isolate was considered resistant when MIC for ITR was \>2 mg/L, POS \> 0.25 mg/L and VOR \> 2 mg/L. It was considered intermediate when MIC for itraconazole was 2 mg/L, posaconazole 0.25 mg/L and voriconazole 2 mg/L.

*A. fumigatus* was equally common among mold-colonized patients at the two centers \[42/49 (85.7%) and 95/110 (86.4%)\], but the proportion of patients with non-susceptible *A. fumigatus* isolates differed. At AUH, non-susceptible *A. fumigatus* isolates were observed in 2/42 (4.8%) patients ([Table 2](#T2){ref-type="table"}). At RH, 10/95 (10.5%) patients carried non-susceptible *A. fumigatus.* Nine of these patients (9.5%) carried 10 azole-R *A. fumigatus.* Eight patients had a *cyp51A* mutation (7.4% of patients), five of which with tandem repeats (TR~34~/L98H or TR~34~^3^/L98H) and three with alterations affecting the M220 codon ([Table 2](#T2){ref-type="table"}). Among the 10 patients with resistant *A. fumigatus*, four patients had only resistant isolates obtained in the study period. These included the resistance mechanisms TR~34~/L98H, TR~34~^3^/L98H, and wild-type. Alternating resistant and susceptible *A. fumigatus* isolates were found in six patients with the resistance mechanisms M220K, TR~34~/L98H, TR~34~/L98H/S297T/F495I, M220R, and wild-type (M220K two patients and one each).

STR*Af* genotyping identified 27 unique STR*Af* genotypes among the 45 *A. fumigatus* isolates from the 12 patients with azole non-susceptible *A. fumigatus* ([Table 3](#T3){ref-type="table"}). Eight patients harbored isolates with more than one genotype. Three of these patients, carried isolates that differed only in a single marker (RH-5, RH-7, and RH-8), and six patients carried isolates that were clearly unrelated (including two patients with both related and unrelated genotypes RH-7). Thus, patient RH-5 had six isolates with 8/9 identical STR*Af* markers, while marker 3A ranged from 95 repeats (TR~34~/L98H) to 96--101 repeats (five TR~34~^3^/L98H) ([Table 3](#T3){ref-type="table"}). In contrast, Patient AUH-2 harbored two TR~34~/L98H isolates but with clearly different STR*Af* profiles. Patient RH-2 harbored 10 *A. fumigatus* with three different genotypes, while patient RH-8 had four isolates with 8/9 identical markers and a fifth isolate with 7/9 identical markers. Isolates that shared 8--9 markers were also found across patients. Thus, patient RH-7 had two TR~34~/L98H isolates with identical STR*Af* profiles as two TR~34~^3^/L98H isolates from RH-5.

###### 

Detailed susceptibility pattern and STRAf genotyping of all *Aspergillus fumigatus* isolates from patients harboring isolates with decreased azole susceptibility.

  Patient ID   MIC (mg/L)   Cyp51A profile   Sample date   Genotype                                                                           
  ------------ ------------ ---------------- ------------- ---------------------------- ------------ ---- ---- ---- ----- ---- ---- ---- ---- ----
  AUH-1        1            0.25             2             Wild-type                    15-05-2018   26   20   8    36    9    6    8    10   20
  AUH-2        \>16         1                4             TR~34~/L98H                  10-01-2018   10   20   10   29    9    6    8    10   19
               \>16         1                8             TR~34~/L98H                  04-04-2018   23   21   16   65    9    9    10   24   21
               \>16^*b*^    0.5              4             TR~34~/L98H                  03-05-2018   23   21   16   65    9    9    10   24   21
  RH-1         1            0.25             2             Wild-type                    22-06-2018   23   23   15   23    11   19   13   9    5
               2            0.25             2             Wild-type                    17-08-2018   23   23   15   23    11   19   13   9    5
  RH-2         \>16         2                2             Wild-type                    08-02-2018   17   12   14   34    65   12   8    9    5
               S            S                S             NA, S                        15-03-2018   18   21   19   22    11   28   10   8    8
               2            0.25             2             Wild-type                    19-04-2018   17   12   14   34    65   12   8    9    5
               S            S                S             NA, S                        19-04-2018   18   21   19   22    11   28   10   8    8
               S            S                S             NA, S                        18-05-2018   18   21   19   22    11   28   10   8    8
               2            1                1             Wild-type                    07-06-2018   17   12   14   34    65   12   8    9    5
               S            S                S             NA, S                        29-06-2018   18   21   19   22    11   28   10   8    8
               S            S                S             NA, S                        16-08-2018   17   12   14   34    65   12   8    9    5
               S            S                S             NA, S                        16-08-2018   18   21   19   22    11   28   10   8    8
               0.5          0.125            2             Wild-type                    20-09-2018   18   21   19   22    11   28   10   8    8
               0.5          0.125            3             Wild-type                    20-09-2018   19   24   20   36    11   17   16   11   8
  RH-3         8            0.25             2             Wild-type                    11-05-2018   21   25   18   27    12   6    21   10   8
  RH-4         \>16         4                8             TR~34~/L98H/S297T/F495I      26-04-2018   14   20   8    40    9    10   8    10   20
               \>16         2                4             TR~34~/L98H/S297T/F495I      20-07-2018   14   20   8    40    9    10   8    10   20
               0.25         0.06             0.5           Wild-type                    23-08-2018   14   20   8    36    9    9    8    10   20
  RH-5         NA           NA               NA            Wild-type                    11-07-2009   25   20   8    10    10   21   9    10   5
               S            S                S             NA, S                        27-01-2010   NA   NA   NA   NA    NA   NA   NA   NA   NA
               \>16         1                4             TR~34~^3^/L98H               25-05-2017   23   21   16   97    9    6    5    9    10
               \>16         1                8             TR~34~^3^/L98H               31-05-2017   23   21   16   96    9    6    5    9    10
               \>16         1                4             TR~34~^3^/L98H               16-01-2018   23   21   16   98    9    6    5    9    10
               \>16         1                4             TR~34~/L98H                  13-02-2018   23   21   16   95    9    6    5    9    10
               \>16         1                4             TR~34~^3^/L98H               13-02-2018   23   21   16   99    9    6    5    9    10
               \>16         1                8             TR~34~^3^/L98H               01-03-2018   23   21   16   101   9    6    5    9    10
  RH-6         \>16         1                8             TR~34~/L98H                  21-06-2018   14   20   17   31    11   9    8    14   20
               \>16         1                8             TR~34~/L98H                  01-10-2018   14   20   17   31    11   9    8    14   20
  RH-7         0.25         0.06             0.5           NA, S                        17-09-2018   14   18   12   34    9    7    8    10   21
               0.125        0.06             0.5           NA, S                        06-09-2018   18   20   9    26    10   6    8    10   5
               8            0.5              4             TR~34~/L98H                  10-05-2018   23   21   16   97    9    6    5    9    10
               \>16         0.5              4             TR~34~/L98H                  05-07-2018   23   21   16   99    9    6    5    9    10
  RH-8         \>16         \>4              2             M220R                        06-02-2018   23   23   15   40    11   46   10   26   8
               \>16         4                1             NA, R                        27-03-2018   23   23   15   40    11   46   10   26   8
               \>16         \>4              2             Mixed, M220R and Wild-type   03-04-2018   23   23   15   40    11   46   10   26   8
               \>16         \>4              2             Mixed, M220R and Wild-type   03-04-2018   23   23   15   41    11   46   10   26   8
               \>16         2                2             Wild-type                    04-09-2018   23   23   15   40    11   45   10   26   8
               0.5          0.25             1             Wild-type                    20-09-2018   23   23   15   37    11   42   10   26   8
  RH-9         \>16         1                1             M220K                        07-03-2018   18   19   11   27    10   37   20   11   5
               0.5          0.125            0.5           NA, S                        27-08-2018   18   28   8    29    11   17   8    8    5
  RH-10        \>16         2                1             M220K                        04-03-2018   11   12   11   17    9    15   8    8    5
               S            S                S             NA, S                        03-05-2018   18   23   26   22    11   25   22   10   8

a

AUH, Aarhus University Hospital, RH, Rigshospitalet. ITR, Itraconazole, POS, Posaconazole, VOR, Voriconazole, S, Susceptible, R, Resistant, NA, Not analyzed.

b

Duplicate isolates and isolates outside the study period are shown in gray.

Azole resistance was also detected in other *Aspergillus* species. At AUH, such isolates were found in 3/49 (6.1%) patients including two patients with *A. thermomutatus*, and one patient with a voriconazole-resistant *A. terreus* isolate with a wild-type *cyp51A* ([Table 2](#T2){ref-type="table"}). At RH, two out of eight CF patients with *A. terreus* (1.8% of CF patients at RH) had non-susceptible isolates. One patient (RH-11) had both resistant and intermediate isolates recovered, which had Cyp51A amino acid substitutions M217I and Y491H, respectively. The other patient had a resistant *A. terreus* with a G51A mutation (RH-12, [Table 2](#T2){ref-type="table"}). MIC distributions for all *Aspergillus* isolates with reduced azole susceptibility at the two centers are shown in [Supplementary Table 1](#TS1){ref-type="supplementary-material"}.

Finally, we investigated potential changes in non-susceptibility and Cyp51A alteration rates in a 10-year perspective by comparison with data from the period 2007-2009 for the RH CF cohort ([@B34], [@B35]). Non-susceptible *A. fumigatus* was observed in 1/61 (1.6%) patients in Q1-2007, 6/133 patients in 2007--9 (4.5%) compared to 10/95 (10.5%) in 2018 (*P* = 0.047). Similarly, the proportion of isolates with Cyp51 alterations in Q1-2007, Q3-4-2007/9, and 2018 increased: 1.6% (95% CI: 0.1--8.7%), 3.8% (95% CI: 1.6--8.5%) and 7.4% (95% CI: 3.6--14.4%), respectively. Finally, the number of patients with resistant isolates with a tandem repeat, specifically, increased during the three study periods: 0% (95% CI: 0--5.9%), 1.5% (95% CI: 0.3--5.3%), and 4.2% (1.6--10.3%), as well as the proportion of isolates with target gene mutations associated with long-term azole treatment: 1.6% (95% CI: 0.8%-8.7%), 2.3% (95% CI: 0.6%-6.4%), and 3.2% (95% CI: 0.9%-8.9%) in Q1-2007, Q3-4-2007/9, and 2018, respectively.

Discussion {#S4}
==========

We report detailed and nationwide data on azole non-susceptibility and mold species distribution in respiratory isolates from Danish CF patients. Azole-R *A. fumigatus* with environmental origin was dominating and found at both centers suggesting a wide geographic distribution of TR~34~/L98H in Denmark. However, although the proportions of patients with *A. fumigatus* (85.7 and 86.3%, respectively) were similar at the two centers, an almost four-fold higher rate of azole-resistant *A. fumigatus* was observed at RH compared to AUH. Moreover, the resistance pattern was more diverse at RH and included both the resistance deriving from the environment and resistance mutations associated with azole treatment selection. Unfortunately, data on azole use in these patients could not be retrieved. However, it is most likely that the differences in azole-R between the two centers may be related to different prescription practices with a more extensive and longer duration of azole treatment at RH, in part due to an overall higher age and number of patients with chronic aspergillus bronchitis at RH. This is supported by the observation that human-driven target gene mutations were more common in patients at RH than at AUH.

At RH, *cyp51A* mutations of environmental origin accounted for half of the detected resistance, and the TR~34~/L98H rate has doubled over the past decade since the first detection in Q3-4 of 2007--9 ([@B34]). Additionally, a subsequent laboratory study of *A. fumigatus* isolates received at the national reference center reported an increase during 2010--2014 ([@B29]). Taken together, these studies suggest that TR~34~/L98H has gradually become more prevalent in Denmark since 2007 despite the fact that two of three environmental sampling studies in Denmark failed to detect TR~34~/L98H and TR~46~/Y121F/T289A in soil and air samples ([@B7]; [@B29]). This suggests either significant fluctuations in the number of resistant spores in the environment or that even low levels of resistant *A. fumigatus* can contribute to resistant infections in a predisposed lung environment.

Our observations of alternating or mixed resistant and susceptible isolates recovered from the same patient is a well-known phenomenon and highlight that a single sample may not be a representation for the entire lung flora ([@B51]; [@B7]). Not only may different phenotypes dominate in different lung sections but mixed *A. fumigatus* strains are also very challenging to identify and separate unless molecular analyses are performed. Of note, two TR~34~/L98H isolates with different and unique STR*Af* genotypes among our collection were recovered from patient AUH-2, a case which we have not previously seen in DK.

Of particular interest, patient RH-5 harbored five pan-azole-resistant isolates with a novel TR~34~^3^/L98H resistance mechanism, which to our knowledge has not previously been found in clinical specimens. However, exposure *in vitro* of *A. fumigatus* conidia already containing a 34-bp insertion in the *cyp51A*-gene promoter to 8 mg/L of tebuconazole resulted in one clone with a 34-bp triplicate repeat ([@B47]). In addition, the TR~46~/Y121F/T289A has also been found with additional 46-bp repeats in the promoter region in compost as well during sexual mating in *in vitro* studies ([@B54]). The question remains whether this TR~34~^3^/L98H resistance variant is novel in the environment and thus acquired *de novo*, as suggested by being isolated first, or whether the TR~34~/L98H was in fact first (but undiscovered in the first three specimens) and the additional TR~34~ repeat acquired *in vivo*. The STR*Af* profiles suggest that the five TR~34~^3^/L98H isolates are isogenic with a classical example of microevolution. It is noteworthy that the TR~34~/L98H isolate from this patient shared 8/9 markers and had 95 repeats at marker 3A while an increasing number of repeats (96--101) were seen in the TR~34~^3^/L98H isolates over time. Increasing repeat numbers have previously been found over time *in vitro* and *in vivo* ([@B34]; [@B14]). Furthermore, the TR~34~/L98H strain was discovered in a sample mixed with the TR~34~^3^/L98H strain and had a white and slow-growing phenotype, which could help explain why it could potentially have been overlooked in earlier samples. Indeed, the *in vivo* acquisition of a tandem repeat in the promotor region has been reported from our group, where a 120-basepair tandem repeat evolved in a patient during azole therapy, supported by whole-genome sequencing (WGS) ([@B26]). It has also been suggested that the TR~34~ helps compensate for loss of fitness associated with the L98H change ([@B52]) and thus the additional TR~34~ could potentially further improve fitness and outgrow the TR~34~/L98H, which in this patient appeared with a weaker phenotype ([@B52]). A third hypothesis could be that this is a random coincidence of similar STR*Af* genotypes. Indeed, the finding of two TR~34~/L98H isolates from another patient (RH-7) displaying identical STR*Af* profiles as two TR~34~^3^/L98H isolates was surprising and further complicates the interpretation. One concern would be lab contamination, but since the two RH-7 isolates were received months apart and with different *cyp51A* profiles, this seems unlikely. A final, and worrying, theory is that we may have encountered a dominating TR~34~/L98H clone in DK similar to the study from India ([@B13]). Indeed, outside the study period we have encountered a total of 20 isolates from 12 different patients from all around DK and also in two air samples sharing the same 8/9 STR*Af* markers, exclusively differing in marker 3A, ranging from 35 to more than 130 repeats. The high variation in 3A (in our two patients) indicates a highly mutagenic strain type, which may help explain the rare development of the TR~34~^3^/L98H variant. Further studies including WGS are desirable to further explore the origin of this novel resistance mechanism as well as the potentially novel dominating genotype.

Two CF patients had resistant *A. fumigatus* with wild-type *cyp51A*, as reported in other CF studies ([@B34]; [@B9]; [@B21]; [@B45]; [@B30]) at similar rates ([@B34]; [@B9]; [@B30]) as well as in patients with chronic pulmonary aspergillosis ([@B27]). Phenotypic susceptibility testing therefore remains crucial because molecular detection of resistance mechanism enables the detection of resistance, but not susceptibility. Moreover, alternating findings of susceptible and non-susceptible isolates in the same patient demonstrate the need of repeated sampling and susceptibility testing of several colonies when present in patients requiring azole therapy, as recommended in current guidelines ([@B50]; [@B22]).

Azole-R *A. terreus* constitutes a significant challenge since *A. terreus* has intrinsic reduced susceptibility to amphotericin B, rendering it multidrug-resistant ([@B4]; [@B55]; [@B43]). The present finding of *A. terreus* of 6.3% (10/159) nationally at patient level is quite high compared to previous studies ([@B34]; [@B18]; [@B16]), reporting 1.9% ([@B34]) and 2.4% *A. terreus* at the isolate level ([@B18]) and 3.9% of all *Aspergillus* spp. ([@B16]). Whereas M217I has been reported previously ([@B43]), G51A is, to our knowledge, novel. We also detected *A. thermomutatus*, another inherently voriconazole-resistant *Aspergillus* spp., at AUH. This species has been detected in one CF patient at RH previously ([@B34]) illustrating that resistant *Aspergillus* infection is not limited to *A. fumigatus* in this setting.

When we compare the present study's result to others, the current overall azole-R rate of 7.3% in the total CF population corresponded well with CF studies from other European countries \[France, Germany, the Netherlands ([@B8]; [@B45]; [@B16]; [@B30]), and the United States ([Table 1](#T1){ref-type="table"})\] ([@B49]). Internationally, published azole resistance rates have varied greatly. No azole resistance was reported from a Portuguese center ([@B2]), in one of two Italian centers ([@B41]), and in five out of 12 German centers ([@B45]; [Table 3](#T3){ref-type="table"}). In contrast, Abdolrasouli et al. found a concerning high resistance rate of 16.2% in CF patients specifically, which could be reflected upon the patient group at a cardiothoracic center in United Kingdom following up CF patients ([@B1]). Guegan et al. also found a high azole-R rate of 15.2%, but in a limited CF population of 33 patients ([@B21]; [Table 1](#T1){ref-type="table"}).

The major strength of the present study is the fact that it allowed a 10-year perspective on azole-resistant *Aspergillus* and a nationwide surveillance perspective of the current mold epidemiology in CF patients in Denmark. Since we also included *Aspergillus* species other than *A. fumigatus*, we also reported mutations in *A. terreus* and furthermore detailed information on STR*Af* genotyping in one patient with *A. fumigatus*. A limitation, however, is that we do not have information regarding the clinical relevance of the retrieved *A. fumigatus*, nor do we have any information regarding preceding antifungal use.

In conclusion, azole-R *Aspergillus* is increasing in proportion and complexity among Danish CF patients. The larger and increasing proportion involved resistant *A. fumigatus* of environmental origin, and novel genotypes in both *A. fumigatus* and *A. terreus* were found. Although the isolation of *Aspergillus* may reflect contamination or transient colonization and thus include patients in whom antifungal therapy is not indicated, the continuously emerging reports of azole-resistant *Aspergillus* is worrisome, and resistance remains a significant challenge. This is of concern as effective alternative treatments to azoles are lacking and as it suggests that azole-resistant *A. fumigatus* may also be an increasing challenge in other patient populations at risk for aspergillus disease.
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